Affiliation:
1. Laboratory of Microbiome, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan
2. Heart Center, CF “University Medical Center”, Astana 010000, Kazakhstan
Abstract
Cardiovascular diseases (CVDs) are a leading cause of global morbidity and mortality, significantly driven by chronic inflammation. Interleukin-6 (IL-6) and interleukin-1β (IL-1β) are critical inflammatory cytokines implicated in CVD progression. This systematic review evaluates the roles of IL-6 and IL-1β in CVDs by synthesizing data from relevant studies to understand their impact on cardiovascular outcomes and identify potential therapeutic interventions. A comprehensive literature search was conducted using PubMed and Embase, covering studies from January 2014 to December 2024. Inclusion criteria encompassed studies investigating IL-6 and/or IL-1β in CVDs, including human and relevant animal models, and reporting clinical outcomes, molecular mechanisms, or therapeutic interventions. Data extraction and quality assessment were performed independently by two reviewers. Our review included 12 studies focusing on the roles of IL-6 and IL-1β in various CVDs. Elevated IL-6 levels were significantly associated with peripheral artery disease, myocardial infarction, and heart failure, while IL-1β levels were linked to worse outcomes in coronary artery disease and heart failure. Meta-analyses indicated a significant association between higher IL-6 and IL-1β levels and increased risk of adverse cardiovascular events. These findings suggest that targeting IL-6 and IL-1β could offer promising therapeutic strategies for reducing inflammation and improving cardiovascular outcomes.
Funder
Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan
Reference54 articles.
1. Role of Cardiac Biomarkers in Epidemiology and Risk Outcomes;Haller;Clin. Chem.,2021
2. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk;Libby;Arterioscler. Thromb. Vasc. Biol.,2019
3. Statins for people at low risk;Parish;BMJ,2015
4. Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004–2015;Blais;Atherosclerosis,2019
5. Salami, J.A., Warraich, H.J., Valero-Elizondo, J., Spatz, E.S., Desai, N.R., Rana, J.S., Virani, S.S., Blankstein, R., Khera, A., and Blaha, M.J. (2018). National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. J. Am. Heart Assoc., 7.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献